2. Signaling Pathways
  3. Immunology/Inflammation
  4. MHC
  5. MHC I Isoform

MHC I

 

MHC I Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-P4193
    AH1
    		99.16%
    AH1 is an immunodominant MHC class I-restricted nonamer peptide recognized by CD8+ cytotoxic T lymphocytes. AH1 derives from the envelope protein (gp70) of an endogenous ecotropic murine leukemia virus and is presented by the MHC class I Ld molecule. AH1 can be used for the research of colorectal carcinoma.
  • HY-P990193
    Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S)
    		Inhibitor
    Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) is an anti-mouse MHC Class I (H-2Kd, H-2Dd) IgG2a monoclonal antibody. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can block the interaction between Ly49 and MHC-I. Anti-Mouse MHC Class I (H-2Kd, H-2Dd) Antibody (34-1-2S) can be used for the construction of acute lung injury models.
  • HY-P6312
    ESAT6 Epitope
    		Ligand
    ESAT6 Epitope is a ESAT6 CD4+ T cell epitope. ESAT6 Epitope binds to MHC class I molecules with an IC50 value of approximately 180 nM. ESAT6 Epitope has weak immunogenicity. ESAT6 Epitope can be used in studies related to pulmonary tuberculosis.
  • HY-152830
    Adrixetinib
    		Activator 99.55%
    Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.
  • HY-152830A
    Adrixetinib TFA
    		Activator 99.82%
    Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma.
  • HY-P992111
    Elfritatug
    		Inhibitor
    Elfritatug (UCB4594) is a humanized monoclonal antibody targeting human leukocyte antigen-G (HLA-G). By binding to HLA-G on the surface of tumor cells, Elfritatug blocks its immunosuppressive effect, thereby enhancing the body's immune response against tumors.
  • HY-P11713
    EBNA3B 399-408
    EBNA3B 399-408 is an immunodominant HLA-A11-restricted cytotoxic T-lymphocyte epitope in EBNA3B. EBNA3B 399-408 can be used in the research of EBV infection, empyema-associated lymphoma, and nasal natural killer cell lymphoma.
  • HY-P11714
    EBNA3 246-254
    EBNA3 246-254 (RYSIFFDYM) is an EBV peptide. EBNA3 246-254 is submitted by HLA-A24. EBNA3 246-254 is amplified in vitro, followed by HLA multimer staining to measure EBV-specific CTLs. EBNA3 246-254 can be used for the research of lung cancer.
  • HY-P11060
    MC38 SLP Adpgk
    MC38 SLP Adpgk (Adpgk peptide) is an H-2 Kb-restricted colorectal cancer neoantigen peptide. MC38 SLP Adpgk is formulated into PCNP nanocomplexes together with CpG ODN. PCNP vaccines significantly enhance the co-delivery efficiency of neoantigens and adjuvants to lymphoid organs, and activate cytotoxic T cells. PCNP vaccines not only protect mice from MC-38 colorectal tumor invasion, but also exhibit anti-tumor efficacy in established colorectal tumor models and significantly prolong the survival of tumor-bearing mice.
  • HY-P11340
    VMAPRTLFL
    		Ligand
    VMAPRTLFL is a 9-mer peptide derived from the signal peptide of HLA-G and can serve as a peptide ligand for HLA-E. VMAPRTLFL plays a crucial role in regulating the functions of adaptive natural killer (NK) cells. Specifically, VMAPRTLFL enriches FcεRγ- adaptive NK cells, upregulates the expression of CD25, and enhances their proliferative activity, antibody-dependent cellular cytotoxicity (ADCC), and IFN-γ release. VMAPRTLFL can be used in research related to human cytomegalovirus (HCMV) infection, transplant rejection, and pregnancy immunity.
  • HY-179211
    CliMB-325
    		Activator
    CliMB-325 is an HSP90 inhibitor that can induce MHC-I (EC50 = 498 nM) expression on the surface of CT26 murine colorectal cancer cells. CliMB-325 enhances T cell activation and exhibits lower toxicity. CliMB-325 can be used for the study of colorectal cancer.